Sartorius AG (STU:SRT) Additional Paid-In Capital : €243 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Sartorius AG Additional Paid-In Capital?

Sartorius AG's quarterly additional paid-in capital increased from Sep. 2023 (€45 Mil) to Dec. 2023 (€45 Mil) and increased from Dec. 2023 (€45 Mil) to Mar. 2024 (€243 Mil).

Sartorius AG's annual additional paid-in capital increased from Dec. 2021 (€43 Mil) to Dec. 2022 (€45 Mil) and increased from Dec. 2022 (€45 Mil) to Dec. 2023 (€45 Mil).

Sartorius AG Additional Paid-In Capital Historical Data

The historical data trend for Sartorius AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Additional Paid-In Capital Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

40.69

41.99

43.30

44.60

45.20

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															44.80	44.90	45.00	45.20	243.40

Sartorius AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sartorius AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (STU:SRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (STU:SRT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.